• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Roivant Sciences

    Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV
    Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Roivant Sciences
    Via GlobeNewswire
    Tickers OGN ROIV
    Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Roivant Sciences
    Via GlobeNewswire
    Tickers OGN ROIV
    Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV
    Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV
    Roivant Provides Update on Graves’ Disease Development Program
    From Roivant Sciences
    Via GlobeNewswire
    Tickers IMVT ROIV
    Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV
    Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV
    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
    From Roivant Sciences
    Via GlobeNewswire
    Tickers IMVT ROIV ROIVW
    Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
    From Roivant Sciences
    Via GlobeNewswire
    Tickers RHHBY ROIV ROIVW
    Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
    From Roivant Sciences
    Via GlobeNewswire
    Tickers IMVT ROIV ROIVW
    Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
    From Roivant Sciences
    Via GlobeNewswire
    Tickers RHHBY ROIV ROIVW
    Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Announces Completion of Redemption of its Outstanding Warrants
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Announces Redemption of Outstanding Warrants
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Tickers ROIV ROIVW
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.